{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:50Z","timestamp":1761512810337},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s10067-010-1484-5","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T03:04:57Z","timestamp":1274151897000},"page":"1049-1054","source":"Crossref","is-referenced-by-count":16,"title":["Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis"],"prefix":"10.1007","volume":"29","author":[{"given":"Hiroshi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishin","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Aizawa-Yashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"1484_CR1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1328-8067.2002.01536.x","volume":"44","author":"S Yokota","year":"2002","unstructured":"Yokota S (2002) Mizoribine: mode of action and effects in clinical use. Pediatr Int 44:196\u2013198","journal-title":"Pediatr Int"},{"key":"1484_CR2","doi-asserted-by":"crossref","first-page":"c73","DOI":"10.1159\/000151721","volume":"110","author":"H Tanaka","year":"2008","unstructured":"Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J (2008) Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract 110:c73\u2013c79","journal-title":"Nephron Clin Pract"},{"key":"1484_CR3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000082202","volume":"24","author":"Y Kawasaki","year":"2004","unstructured":"Kawasaki Y, Hosoya M, Suzuki J, Onishi N, Takahashi A, Isome M, Nozawa R, Suzuki H (2004) Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methyprednisolone pulse therapy. Am J Nephrol 24:576\u2013581","journal-title":"Am J Nephrol"},{"key":"1484_CR4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00467-007-0664-2","volume":"23","author":"Y Ikezumi","year":"2008","unstructured":"Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson DJ, Uchiyama M (2008) Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatr Nephrol 23:645\u2013650","journal-title":"Pediatr Nephrol"},{"key":"1484_CR5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CNP68198","volume":"68","author":"H Tanaka","year":"2007","unstructured":"Tanaka H, Tsugawa K, Oki E, Suzuki K, Waga S, Ito E (2007) Long-term mizoribine intermittent pulse therapy, but not azathioprine therapy, attenuated histologic progression in a patient with severe lupus nephritis. Clin Nephrol 68:198\u2013200 (letter)","journal-title":"Clin Nephrol"},{"key":"1484_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000046065","volume":"89","author":"N Sato","year":"2001","unstructured":"Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, Kobayashi Y, Yamagishi-Imai H, Utsunomiya Y, Mitarai T (2001) Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. Nephron 89:177\u2013185","journal-title":"Nephron"},{"key":"1484_CR7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ndt\/gfh888","volume":"20","author":"Y Kikuchi","year":"2005","unstructured":"Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S (2005) Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 20:1573\u20131581","journal-title":"Nephrol Dial Transplant"},{"key":"1484_CR8","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1159\/000213896","volume":"112","author":"S Takahashi","year":"2009","unstructured":"Takahashi S, Taniguchi Y, Nakashima A, Arakawa T, Kawai T, Doi S, Ito T, Masaki T, Kohno N, Yorioka N (2009) Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model. Nephron Exp Nephrol 112:e59\u2013e69","journal-title":"Nephron Exp Nephrol"},{"key":"1484_CR9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10067-007-0635-9","volume":"27","author":"H Tanaka","year":"2008","unstructured":"Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E (2008) Mizoribine intermittent pulse therapy for induction therapy for systemic lupus erythematosus in children: an open label pilot study with five newly diagnosed patients. Clin Rheumatol 27:85\u201389","journal-title":"Clin Rheumatol"},{"key":"1484_CR10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ki.1984.75","volume":"25","author":"HA Austin","year":"1984","unstructured":"Austin HA, Muenz LR, Joyce KM, Antonnovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:689\u2013695","journal-title":"Kidney Int"},{"key":"1484_CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/096120300678828640","volume":"9","author":"M Mosca","year":"2000","unstructured":"Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S (2000) The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 9:445\u2013450","journal-title":"Lupus"},{"key":"1484_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"274","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H (2000) Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 274:87\u201392","journal-title":"Biochem Biophys Res Commun"},{"key":"1484_CR13","doi-asserted-by":"crossref","first-page":"35147","DOI":"10.1074\/jbc.274.49.35147","volume":"274","author":"H Itoh","year":"1999","unstructured":"Itoh H, Komatsuda A, Wakui H, Miura AB, Tashima Y (1999) Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biol Chem 274:35147\u201335151","journal-title":"J Biol Chem"},{"key":"1484_CR14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1620\/tjem.218.49","volume":"218","author":"Y Kawasaki","year":"2009","unstructured":"Kawasaki Y, Suyama K, Go H, Imamura T, Ushijima Y, Sakai N, Hashimoto K, Hosoya M (2009) Accumulation of macrophages expressing myeloid-related protein 8 associated with the progression of sclerotic changes in children with IgA nephropathy. Tohoku J Exp Med 218:49\u201355","journal-title":"Tohoku J Exp Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1484-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1484-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1484-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:41Z","timestamp":1559119901000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1484-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1484-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]}}}